Journal ArticleDOI
Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study.
Ján Rosa,Petr Widimský,Petr Waldauf,Tomáš Zelinka,Ondřej Petrák,Miloš Táborský,Marian Branny,Petr Tousek,Karol Curila,Lukas Lambert,František Bednář,Robert Holaj,Branislav Štrauch,Jan Václavík,Eva Kociánová,Igor Nykl,Otakar Jiravský,Gabriela Rappová,T. Indra,Zuzana Krátká,Jiří Widimský +20 more
TLDR
In the settings of true resistant hypertension, spironolactone addition (if tolerated) seems to be of better efficacy than RDN in BP reduction over a period of 24 months, however, by contrast to the 12-month results, BP changes were not significantly greater.Abstract:
Objectives:The randomized, multicentre study compared the efficacy of renal denervation (RDN) versus spironolactone addition in patients with true resistant hypertension. We present the 24-month data.Methods:A total of 106 patients with true resistant hypertension were enrolled in this study: 52 patread more
Citations
More filters
Journal ArticleDOI
Report of the National Heart, Lung, and Blood Institute Working Group on the Role of Microbiota in Blood Pressure Regulation: Current Status and Future Directions.
Mohan K. Raizada,Bina Joe,Nathan S. Bryan,Eugene B. Chang,Floyd E. Dewhirst,Gary G. Borisy,Zorina S. Galis,Wendy A. Henderson,Pedro A. Jose,Christian J. Ketchum,Christian J. Ketchum,Johanna W. Lampe,Carl J. Pepine,Jennifer L. Pluznick,Dominic Raj,Douglas R. Seals,Rachel A. Gioscia-Ryan,W.H. Wilson Tang,Young S. Oh +18 more
TL;DR: The SPRINT (Systolic Blood Pressure Intervention Trial) as mentioned in this paper showed that among older adults with hypertension but without diabetes mellitus, lowering systolic blood pressure to a target goal of 120 mm Hg, compared with the standard goal of 140 mmµhg, resulted in significantly lower rates of fatal and nonfatal cardiovascular events and death from any cause.
Journal ArticleDOI
Renal denervation for resistant hypertension.
TL;DR: The short- and long-term effects of renal denervation in individuals with resistant hypertension on clinical end points, including fatal and non-fatal cardiovascular events, all-cause mortality, hospital admissions, quality of life, blood pressure control, left ventricular hypertrophy, cardiovascular and metabolic profile, and kidney function are evaluated, as well as the potential adverse events related to the procedure.
Journal ArticleDOI
[op.7d.09] the role of adding spironolactone and renal denervation in true resistant hypertension. one-year outcomes of randomized prague-15 study
Ján Rosa,Petr Widimsky,Petr Waldauf,Lukas Lambert,Tomáš Zelinka,Milos Taborsky,Marian Branny,Petr Tousek,Ondřej Petrák,Karol Curila,F. Bednar,Robert Holaj,Branislav Štrauch,Jan Václavík,Igor Nykl,Zuzana Krátká,Eva Kociánová,O. Jiravsky,T. Indra,J. Widimsky +19 more
TL;DR: This study shows that RDN is safe, with no serious side effects and no major changes in the renal arteries, and spironolactone addition (if tolerated) seems to be more effective in BP reduction.
Journal ArticleDOI
Cost-Effectiveness of Renal Denervation Therapy for Treatment-Resistant Hypertension: A Best Case Scenario.
Enayet K. Chowdhury,Christopher M. Reid,Christopher M. Reid,Ella Zomer,Darren J. Kelly,Danny Liew +5 more
TL;DR: At current costs and based on currently observed effects on BP reduction, RDN would be cost-effective among patients with TRH.
Journal ArticleDOI
Specific Activation of the Alternative Cardiac Promoter of Cacna1c by the Mineralocorticoid Receptor.
Thassio R. Mesquita,Gaelle Auguste,Débora Falcón,Gema Ruiz-Hurtado,Rogelio Salazar-Enciso,Jessica Sabourin,Florence Lefebvre,Say Viengchareun,Hussein Kobeissy,Patrick Lechêne,Valérie Nicolas,Amaya Fernández-Celis,Susana Gomez,Sandra Lauton Santos,Eric Morel,Angélica Rueda,Natalia López-Andrés,Ana María Gómez,Marc Lombès,Jean-Pierre Benitah +19 more
TL;DR: The results reveal that MR acts as a transcription factor to translate aldosterone signal into specific cardiac P1-promoter activation that might influence the therapeutic outcome of cardiovascular diseases.
References
More filters
Journal ArticleDOI
2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).
Giuseppe Mancia,Robert Fagard,Krzysztof Narkiewicz,Josep Redon,Alberto Zanchetti,Michael Böhm,Thierry Christiaens,Renata Cifkova,Guy De Backer,Anna F. Dominiczak,Maurizio Galderisi,Diederick E. Grobbee,Tiny Jaarsma,Paulus Kirchhof,Sverre E. Kjeldsen,Stéphane Laurent,Athanasios J. Manolis,Peter M. Nilsson,Luis M. Ruilope,Roland E. Schmieder,Per Anton Sirnes,Peter Sleight,Margus Viigimaa,Bernard Waeber,Faiez Zannad,Michel Burnier,Ettore Ambrosioni,Mark Caufield,Antonio Coca,Michael H. Olsen,Costas Tsioufis,Philippe van de Borne,José Luis Zamorano,Stephan Achenbach,Helmut Baumgartner,Jeroen J. Bax,Héctor Bueno,Veronica Dean,Christi Deaton,Çetin Erol,Roberto Ferrari,David Hasdai,Arno W. Hoes,Juhani Knuuti,Philippe Kolh,Patrizio Lancellotti,Aleš Linhart,Petros Nihoyannopoulos,Massimo F Piepoli,Piotr Ponikowski,Juan Tamargo,Michal Tendera,Adam Torbicki,William Wijns,Stephan Windecker,Denis Clement,Thierry C. Gillebert,Enrico Agabiti Rosei,Stefan D. Anker,Johann Bauersachs,Jana Brguljan Hitij,Mark J. Caulfield,Marc De Buyzere,Sabina De Geest,Geneviève Derumeaux,Serap Erdine,Csaba Farsang,Christian Funck-Brentano,Vjekoslav Gerc,Giuseppe Germanò,Stephan Gielen,Herman Haller,Jens Jordan,Thomas Kahan,Michel Komajda,Dragan Lovic,Heiko Mahrholdt,Jan Östergren,Gianfranco Parati,Joep Perk,Jorge Polónia,Bogdan A. Popescu,Zeljko Reiner,Lars Rydén,Yuriy Sirenko,Alice Stanton,Harry A.J. Struijker-Boudier,Charalambos Vlachopoulos,Massimo Volpe,David A. Wood +89 more
TL;DR: In this article, a randomized controlled trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly people was presented. But the authors did not discuss the effect of the combination therapy in patients living with systolic hypertension.
Journal ArticleDOI
A Controlled Trial of Renal Denervation for Resistant Hypertension
Deepak L. Bhatt,David E. Kandzari,John M. Flack,Barry T. Katzen,Martin B. Leon,Minglei Liu,Laura Mauri,Manuela Negoita,Sidney Cohen,Suzanne Oparil,Krishna J. Rocha-Singh,Raymond R. Townsend,George L. Bakris,Abstr Act +13 more
TL;DR: This blinded trial did not show a significant reduction of systolic blood pressure in patients with resistant hypertension 6 months after renal-artery denervation as compared with a sham control.
Journal ArticleDOI
Renal Sympathetic-Nerve Ablation for Uncontrolled Hypertension
TL;DR: The renal sympathetic nerves have been identified as a major contributor to the complex pathophysiology of hypertension in both experimental models and in humans and may be modulated by afferent signaling from renal sensory nerves.
Journal ArticleDOI
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial
Bryan Williams,Thomas M. MacDonald,Steve Morant,David J. Webb,Peter S. Sever,Gordon T. McInnes,Ian Ford,J. Kennedy Cruickshank,Mark J. Caulfield,Jackie Salsbury,Isla S. Mackenzie,Sandosh Padmanabhan,Morris J. Brown +12 more
TL;DR: Spironolactone was the most effective blood pressure-lowering treatment, throughout the distribution of baseline plasma renin; but its margin of superiority and likelihood of being the best drug for the individual patient were many-fold greater in the lower than higher ends of the distribution.
Journal ArticleDOI
Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial
Michel Azizi,Michel Azizi,Marc Sapoval,Marc Sapoval,Philippe Gosse,Matthieu Monge,Guillaume Bobrie,Pascal Delsart,Marco Midulla,Claire Mounier-Vehier,Pierre-Yves Courand,Pierre Lantelme,Pierre Lantelme,Thierry Denolle,C. Dourmap-Collas,Hervé Trillaud,Helena Pereira,Pierre-François Plouin,Gilles Chatellier,Gilles Chatellier +19 more
TL;DR: In patients with well defined resistant hypertension, renal denervation plus an SSAHT decreases ambulatory blood pressure more than the same SSA HT alone at 6 months, and this additional blood pressure lowering effect may contribute to a reduction in cardiovascular morbidity if maintained in the long term after renal Denervation.
Related Papers (5)
Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial
Raymond R. Townsend,Felix Mahfoud,Felix Mahfoud,David E. Kandzari,Kazuomi Kario,Stuart J. Pocock,Michael A. Weber,Sebastian Ewen,Konstantinos Tsioufis,Dimitrios Tousoulis,Andrew S.P. Sharp,A. Watkinson,Roland E. Schmieder,Axel Schmid,James W. Choi,Cara East,Anthony Walton,Ingrid Hopper,Debbie L. Cohen,Robert L. Wilensky,David P. Lee,Adrian Ma,Chandan Devireddy,Janice P. Lea,Philipp Lurz,Karl Fengler,Justin E. Davies,Neil Chapman,Sidney Cohen,Vanessa DeBruin,Martin Fahy,Denise E Jones,Martin T. Rothman,Michael Böhm,Jiro Aoki,Bryan Batson,George Dangas,Shukri David,David E. Kandzari,Manesh R. Patel,Kiritkumar Patel,Jasvindar Singh,Thomas Weber,Joachim Weil,Thomas Zeller,Khaled M. Ziada,Kengo Tanabe,Robert Wilkins,Johanna Contreras,Susan Steigerwalt,Denise Reedus,Satoshi Hoshide,Laura P. Svetkey,Anjani Rao,Angela L. Brown,Markus Suppan,Tolga Agdirlioglu,Elias Noory,Craig Chasen +58 more
Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial
David E. Kandzari,Michael Böhm,Felix Mahfoud,Felix Mahfoud,Raymond R. Townsend,Michael A. Weber,Stuart J. Pocock,Konstantinos Tsioufis,Dimitrios Tousoulis,James W. Choi,Cara East,Sandeep Brar,Sidney Cohen,Martin Fahy,Garrett Pilcher,Kazuomi Kario,Jiro Aoki,Bryan Batson,Debbie L. Cohen,George Dangas,Shukri David,Justin E. Davies,Chandan Devireddy,David E. Kandzari,David P. Lee,Philipp Lurz,Vasilios Papademetriou,Manesh R. Patel,Kiritkumar Patel,Roland E. Schmieder,Andrew S.P. Sharp,Jasvindar Singh,Antony Walton,Thomas Weber,Joachim Weil,Thomas Zeller,Khaled M. Ziada,Kengo Tanabe,Robert Wilkins,Robert L. Wilensky,Johanna Contreras,Susan Steigerwalt,Neil Chapman,Janice P. Lea,Denise Reedus,Satoshi Hoshide,Adrian Ma,Karl Fengler,Ping Li,Laura P. Svetkey,Anjani Rao,Axel Schmid,A. Watkinson,Angela L. Brown,Ingrid Hopper,Markus Suppan,Tolga Agdirlioglu,Elias Noory,Craig Chasen +58 more
Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial
Michel Azizi,Michel Azizi,Marc Sapoval,Marc Sapoval,Philippe Gosse,Matthieu Monge,Guillaume Bobrie,Pascal Delsart,Marco Midulla,Claire Mounier-Vehier,Pierre-Yves Courand,Pierre Lantelme,Pierre Lantelme,Thierry Denolle,C. Dourmap-Collas,Hervé Trillaud,Helena Pereira,Pierre-François Plouin,Gilles Chatellier,Gilles Chatellier +19 more
Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial
Michel Azizi,Michel Azizi,Roland E. Schmieder,Felix Mahfoud,Felix Mahfoud,Michael A. Weber,Joost Daemen,Justin E. Davies,Jan Basile,Ajay J. Kirtane,Yale Wang,Melvin D. Lobo,Manish Saxena,Lida Feyz,Florian Rader,Philipp Lurz,Jeremy Sayer,Marc Sapoval,Marc Sapoval,Terry Levy,Kintur Sanghvi,Josephine Abraham,Andrew S.P. Sharp,Naomi D.L. Fisher,Michael J. Bloch,Helen Reeve-Stoffer,Leslie Coleman,Christopher M. Mullin,Laura Mauri,Laura Mauri,Desmond Jay,Nedaa Skeik,Robert S. Schwartz,Suhail Dohad,Ronald G. Victor,Josh Costello,Courtney Walsh,Theophilus Owan,Anu Abraham,Piotr Sobieszczky,Jonathan S. Williams,Chanwit Roongsritong,Thomas M. Todoran,Eric R. Powers,Emily Hodskins,Pete Fong,Cheryl L. Laffer,James Gainer,Mark Robbins,John P. Reilly,Michael Cash,Jessie Goldman,Sandeep Aggarwal,Gary Ledley,David H. Hsi,Scott Martin,Edward Portnay,David A. Calhoun,Thomas McElderry,William Maddox,Suzanne Oparil,Pei-Hsiu Huang,Powell Jose,Matheen Khuddus,Suzanne Zentko,James O'Meara,Ilie Barb,Joseph Garasic,Doug Drachman,Randy Zusman,Kenneth Rosenfield,Chandan Devireddy,Janice P. Lea,Bryan Wells,Rick Stouffer,Alan L. Hinderliter,Eric Pauley,Srinivasa Potluri,Scott Biedermann,Sripal Bangalore,Stephen Williams,David A. Zidar,Mehdi H. Shishehbor,Barry Effron,Marco Costa,Jai Radhakrishnan,Anthony Mathur,Ajay Jain,Sudha Ganesh Iyer,Nicholas M Robinson,Sadat Ali Edroos,Amit N. Patel,David Beckett,Clare Bent,Neil Chapman,Matthew J. Shun-Shin,James P. Howard,Anil Joseph,Richard D'Souza,Robert Gerber,Mohamad Faris,Andrew J. Marshall,Cristina Elorz,Robert Höllriegel,Karl Fengler,Karl-Philipp Rommel,Michael Böhm,Sebastian Ewen,Jelena Lucic,Christian Ott,Axel Schmid,Michael Uder,L. Christian Rump,Johannes Stegbauer,Patric Kröpil,Erika Cornu,David Fouassier,Philippe Gosse,Antoine Cremer,Hervé Trillaud,Panteleimon Papadopoulos,Atul Pathak,Benjamin Honton,Pierre Lantelme,Constance Berge,Pierre-Yves Courand,Peter J. Blankestijn,Michiel Voskuil,Zwaantina Rittersma,A. A. Kroon,W. H. Van Zwam,Alexandre Persu,Jean Renkin +132 more